Bharathi Vennapusa

Statistics

Publications

Citations

2.2K

H-Index

Active since

2011

Affiliations

Ventana Research Corporation (United States)(Current)

Roche (United States)

The University of Texas MD Anderson Cancer Center

Bharathi Vennapusa is an author at Ventana Research Corporation (United States) specializing in medicine, oncology, and programmed death-ligand 1 biomarker.

Publications per year

2011–2020

Publications

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

Fred R. Hirsch, Abigail McElhinny, Dave Stanforth et al. · Journal of Thoracic Oncology · 2016 · 1.3K citations · Full text

Medicine, Cancer Biology, Oncology +14

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Charles M. Rudin, M. Catherine Pietanza, Todd M. Bauer et al. · The Lancet Oncology · 2016 · 553 citations · Full text

Medicine, Oncology, Pharmacology +15

Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab

Bharathi Vennapusa, Brian M. Baker, Marcin Kowanetz et al. · Applied immunohistochemistry & molecular morphology · 2018 · 189 citations · Full text

Medicine, Immunology, Oncology +17

Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N

Jacquelyn Smith, Mark D. Robida, Krista Acosta et al. · Diagnostic Pathology · 2016 · 72 citations · Full text

Medicine, Immunology, Oncology +17

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma

Ahmed O. Kaseb, Manal M. Hassan, Şahin Laçin et al. · Oncotarget · 2016 · 51 citations · Full text

Medicine, Oncology, Pathology +17

1–5 of 7